Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Publikováno v:
Biochemical and biophysical research communications. 560:1-6
Cancer immunotherapy, especially treatment with monoclonal antibodies (mAbs) that block programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling, has attracted attention as a new therapeutic option for cancer. However, only a l
Autor:
Masakazu Shinohara, Makoto Imamori, Wataru Ogawa, Tetsuya Hosooka, Yusei Hosokawa, Kei Yoshino, Chikako Aoki
Publikováno v:
Biochemical and Biophysical Research Communications. 557:62-68
Clinical and animal studies have suggested a possible beneficial effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH). Although SGLT2 inhibitors have bee
Autor:
Chikako Nishigori, Ikuko Yano, Tsutomu Nakagawa, Takeshi Hirano, Toshinori Bito, Takahiro Ishida, Kazuhiro Yamamoto, Hiroaki Shichiri, Midori Hirai, Maya Tokura, Atsushi Uda
Publikováno v:
Biochemical and Biophysical Research Communications. 485(2):227-233
Hand-foot skin reaction (HFSR) is a common side effect of multiple tyrosine kinase inhibitors (mTKIs). HFSR can necessitate dose reductions or interruption of therapy owing to its negative effect on the quality of life. Therefore, effective use of mT
Autor:
Jeong-Hwan Yoon, Masahiko Kuroda, Keiji Miyazawa, Eunjin Bae, Tatsuo Ohira, Mitsuyasu Kato, Mizuko Mamura, Yojiro Makino, Norihiko Ikeda
Publikováno v:
Biochemical and biophysical research communications. 484(2):269-277
Cancer-associated inflammation develops resistance to the epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) harboring oncogenic EGFR mutations. Stat3-mediated interleukin (IL)-6 signalin
Publikováno v:
Biochemical and Biophysical Research Communications. 477(3):515-519
Patients with pancreatic ductal adenocarcinoma (PDAC) commonly require chemotherapy because they frequently develop metastatic disease or locally advanced tumors. Gemcitabine, an analogue of cytosine arabinoside, is commonly used for PDAC treatment.